Skip to main content
Search
Home    /    Insights & Resources

Insights & Resources

Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.

Life sciences companies often overlook SOX in IPO prep. Discover how early action and targeted strategies can strengthen investor confidence.
As risk evolves, life science companies must adapt valuation methods. Learn to better align risk, value and strategy in your decision-making process.
From payroll to document management, see how accounting automation enhances accuracy, speeds up closes and reduces manual work.
J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.
Although the SEC withdrew its climate disclosure rule, state and international regulations still require businesses to manage emissions and climate risks.
Wyoming House Bill 11 expands the manufacturing sales and use tax exemptions. We break down what this means for businesses operating in Wyoming.
Discover how outsourcing in pharmaceutical manufacturing enhances quality, ensures compliance and mitigates risks in a rapidly evolving industry.
Learn how HMRC's guidelines impact transfer pricing for life sciences and other multinationals and how to mitigate risks and ensure compliance.
Establishing effective ESG KPIs is critical in today’s complex environment. We outline key considerations to drive sustainable success.
Weaver conducted a climate risk analysis to assess and mitigate natural disaster impacts, ensuring resilience and sustainability in our U.S. locations.
The National Association of Manufacturers (NAM) has released its Q4 Manufacturers’ Survey. Learn more about what it means for leadership in 2025.
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
1 2 3 4 62